1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Zandelisib, Rituximab, Venetoclax - CLL | Phase 2 | Withdrawn | MEI Pharma, Inc. | 2022-11-22 | 2023-03-16 |
Leukemia (1)
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
ME-401 (1) · Rituximab (1) · venetoclax (1)
MEI Pharma, Inc. (1)
United States (1)